1 Center for Hepatitis C, Wellstar Atlanta Medical Center, Medical College of Georgia, Department of Medicine, Emory School of Medicine, Atlanta, Georgia, USA.
2 Department of Medicine, Medical College of Georgia, Augusta, Georgia, USA.
3 Center for Hepatitis C, Wellstar Atlanta Medical Center, Mercer School of Medicine, Macon, Georgia, USA.
Chronic hepatitis C-infected patients who do not respond to nonstructural 5A inhibitor-containing regimens have few treatment options. It is unclear if patients who fail glecaprevir/pibrentasvir (G/P) (Mavyret) can be re-treated with sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) (Vosevi) because the latter's registration trials antedated the availability of the former.
Adherent virologic failures to G/P were re-treated with 12 weeks of SOF/VEL/VOX, and all subjects underwent resistance testing at baseline and again with subsequent relapse.
Ninety-four percent of subjects achieved sustained virologic response with re-treatment, despite 90% of 31 subjects harboring nonstructural 5A inhibitor resistance-associated mutations at baseline.
SOF/VEL/VOX is an effective regimen for virologic failures to G/P.